Short-Term Efficacy and Safety Profile of Generic Bortezomib in the Treatment of Multiple Myeloma].

Rong-Qiong Liao, Xiao-Jing Lin, Xiang-Long Li, Xun Ni, Wen-Feng Luo, Pan Zhao, Jing Chen, Jin Wei, Xing-Li Zou

Zhongguo shi yan xue ye xue za zhi 2021 Feb

filter terms:

To investigate the short-term efficacy and safety of generic bortezomib in the treatment of Chinese patients with multiple myeloma (MM). Clinical data of 62 MM patients (median age of 62 years) who had accepted at least 2 cycles of chemotherapy based on generic bortezomib in our center from December 2017 to July 2019 were retrospectively analyzed, including 47 newly diagnosed patients and 15 with disease recurrence or progression. Anemia, renal dysfunction, hypoproteinemia and high level of β 2-microglobulin were all improved rapidly after induction treatment. In 56 patients who had completed at least 4 cycles of chemotherapy, the overall response rate (ORR) was 85.7%, and 64.3% of the patients achieved very good partial response (VGPR) or better, and 28.6% achieved complete remission (CR) or better. In the 19 patients who had already completed all planned induction and consolidation treatment (9 cycles of chemotherapy or 4-6 cycles of chemotherapy plus autologous hematopoietic stem cell transplantation), 84.2% achieved VGPR or better, and 57.9% achieved CR or stringent complete remission (sCR). Median follow-up time was 300 days with data cut-off date of September 20, 2019, and the progression-free survival (PFS) rate and overall survival (OS) rate were 62.1% and 85.3%, respectively. The possible adverse reactions associated with bortezomib were grade 1-2, the most common hematologic adverse reaction was thrombocytopenia (27.4%), and the most common non-hematologic adverse reaction was peripheral neuropathy (43.5%), followed by asthenia (37.1%). The disease severity can be rapidly alleviated after generic bortezomib-based chemotherapy, and a favorable short-term efficacy and survival have been observed with a generally acceptable toxicity profile. However, the long-term outcomes will be examined through further follow-up.

Citation

Rong-Qiong Liao, Xiao-Jing Lin, Xiang-Long Li, Xun Ni, Wen-Feng Luo, Pan Zhao, Jing Chen, Jin Wei, Xing-Li Zou. Short-Term Efficacy and Safety Profile of Generic Bortezomib in the Treatment of Multiple Myeloma]. Zhongguo shi yan xue ye xue za zhi. 2021 Feb;29(1):137-144